These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34533439)

  • 1. Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment.
    Mody D; Bouckaert J; Savvides SN; Gupta V
    Curr Pharm Des; 2021; 27(45):4610-4629. PubMed ID: 34533439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advancement of HDAC inhibitors against breast cancer.
    Mehmood SA; Sahu KK; Sengupta S; Partap S; Karpoormath R; Kumar B; Kumar D
    Med Oncol; 2023 Jun; 40(7):201. PubMed ID: 37294406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current trends in development of HDAC-based chemotherapeutics.
    Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
    Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
    Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
    Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
    Ganai SA
    Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
    Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
    Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
    Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
    J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
    Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
    Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
    Uba AI; Yelekçi K
    J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discussion on structure classification and regulation function of histone deacetylase and their inhibitor.
    Han H; Feng X; He T; Wu Y; He T; Yue Z; Zhou W
    Chem Biol Drug Des; 2024 Jan; 103(1):e14366. PubMed ID: 37776270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
    Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
    J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
    Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
    Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update.
    Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A
    Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.
    Hanigan TW; Aboukhatwa SM; Taha TY; Frasor J; Petukhov PA
    Cell Chem Biol; 2017 Nov; 24(11):1356-1367.e8. PubMed ID: 28943357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
    Beumer JH; Tawbi H
    Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.